3-D Matrix,Ltd. (7777) Stock Price

Three-D Matrix is a company engaged in research and development, manufacturing, and sales of medical products based on self-assembling peptide technology. The company holds an exclusive license to this technology from MIT and applies it to develop medical devices and pharmaceuticals in the surgical, tissue regeneration, and drug delivery system (DDS) fields.

The company's medical product business operates as a single segment. In the surgical field, it develops absorbable hemostatic agents, mucosal elevation materials, and adhesion prevention materials. In tissue regeneration, it develops wound healing materials and alveolar bone reconstruction materials. In the DDS field, it provides drug delivery system technology for nucleic acid therapeutics.

Three-D Matrix's core technology, self-assembling peptides, forms nanofibers and gels under specific conditions. Because this technology does not contain biological source materials and is produced through chemical synthesis, it offers high safety, uniform quality, and enables large-scale production.

The company advances technology development through collaborative research with external institutions. Product manufacturing is outsourced to Fuso Pharmaceutical Industries and Pharmpure. Sales are conducted through an exclusive distribution agreement with FUJIFILM in Europe, while the company employs direct sales in the United States, Japan, and Australia.

Three D Matrix is advancing product development in the surgical and tissue regeneration fields under its corporate mission to "contribute to medical progress through biomaterials." To gain global competitiveness, the company aims to establish stable supply and sales systems, and is allocating management resources toward expanding applications both domestically and internationally.

As a medical device developer, Three D Matrix is promoting global expansion of products for which manufacturing and sales approval is expected. The company is also focusing on commercializing next-generation pipeline candidates and strengthening collaboration with research institutions. Through these efforts, the company aims to realize product commercialization early and stabilize business revenue.

Three D Matrix plans business revenue from product sales of ¥9,283 million for the fiscal year ending April 2026. Research and development expenses are positioned as a key management metric, with efficient management planned at ¥951 million for the fiscal year ending April 2026. This supports the sharing and optimization of basic research.

The company is addressing business revenue expansion and cost reduction by narrowing its focus to the gastrointestinal endoscopy field, thereby reducing marketing expenses and prioritizing revenue generation. In priority areas such as next-generation hemostatic materials, the company is minimizing costs and development time.

For funding, Three D Matrix is securing stable business capital through fundraising from U.S. investment funds and a commitment line agreement with Resona Bank. This strengthens the company's financial foundation on a continuous basis.

Strengthening research and development systems and management structures is also a key priority. The company is enhancing risk management to support global expansion, continuing compliance activities, and establishing internal control systems. The company is also focusing on securing and developing personnel with specialized expertise.